Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.

SG&A Expenses: Bausch Health vs. Xencor Over a Decade

__timestampBausch Health Companies Inc.Xencor, Inc.
Wednesday, January 1, 201420263000007461000
Thursday, January 1, 2015268270000011960000
Friday, January 1, 2016281000000013108000
Sunday, January 1, 2017258200000017501000
Monday, January 1, 2018247300000022472000
Tuesday, January 1, 2019255400000024286000
Wednesday, January 1, 2020236700000029689000
Friday, January 1, 2021262400000038837000
Saturday, January 1, 2022262500000047489000
Sunday, January 1, 2023291700000053379000
Loading chart...

Data in motion

A Decade of SG&A: Bausch Health vs. Xencor

In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is paramount. Over the past decade, Bausch Health Companies Inc. and Xencor, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Bausch Health, a giant in the sector, consistently reported SG&A expenses averaging around $2.57 billion annually, peaking at $2.92 billion in 2023. This reflects a steady growth of approximately 44% from 2014. In stark contrast, Xencor, a smaller biotech firm, maintained a more modest SG&A expenditure, starting at $7.46 million in 2014 and rising to $53.38 million by 2023, marking a significant increase of over 600%. This divergence highlights the varied approaches to operational costs, with Bausch focusing on scale and Xencor on strategic growth. As the industry continues to evolve, these insights offer a glimpse into the financial strategies shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025